Product Information

ROFLUMILAST 250 MCG TABLET is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $1.5343 per EA under NDC 68382062431. Its NADAC has been published 137 times since Apr 10, 2024.

FDA first approved this application on Feb 10, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

ROFLUMILAST 250 MCG TABLET

Roflumilast
$1.5343per EA

Strength

250 ug/1

NDC

68382062431

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Effective Date

11/18/2026

Active Ingredients

ROFLUMILAST

Approval Type

Generic (ANDA)

FDA Application

ANDA208303

FDA Approved

2/10/2022

TE Code

AB

On Market Since

5/18/2023

Pharmacological Classes

Phosphodiesterase 4 Inhibitor
Phosphodiesterase 4 Inhibitors

Price Statistics

The NADAC for ROFLUMILAST 250 MCG TABLET has been published 137 times since Apr 10, 2024, and over the history we have for it it has declined 49.1%. The table below summarizes its recorded NADAC range and movement.

Current price$1.5343 per EA
All-time high$3.0148 (Apr 10, 2024)
All-time low$1.5343 (Nov 18, 2026)
52-week high$2.3109
52-week low$1.5343
Median price$2.3109
Average price$2.2569
Largest weekly change+63.4% (Aug 21, 2024)
Weeks tracked137
Tracking sinceApr 10, 2024

Price History

1W

-15.0%

1M

-22.6%

3M

-23.2%

6M

-21.3%

1Y

-33.6%

3Y

N/A

5Y

N/A

All

-49.1%

Generic Alternatives

The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of ROFLUMILAST 250 MCG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for ROFLUMILAST 250 MCG TABLET, manufactured by Zydus Pharmaceuticals (USA) Inc., is $1.5343 per EA (NDC 68382062431), effective Nov 18, 2026.

How has the price of ROFLUMILAST 250 MCG TABLET changed over time?

Over the history we have for it, the NADAC for ROFLUMILAST 250 MCG TABLET has declined 49.1%. It has been tracked across 137 weekly CMS publications since Apr 10, 2024.

What are the highest and lowest recorded NADAC prices for ROFLUMILAST 250 MCG TABLET?

Since Apr 10, 2024, the NADAC for ROFLUMILAST 250 MCG TABLET has ranged from a low of $1.5343 (Nov 18, 2026) to a high of $3.0148 (Apr 10, 2024), with a median of $2.3109 per EA.

Are there cheaper alternatives to ROFLUMILAST 250 MCG TABLET?

5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ROFLUMILAST 250 MCG TABLET in a comparable dosage form, but none are currently priced below it.

Who manufactures ROFLUMILAST 250 MCG TABLET?

ROFLUMILAST 250 MCG TABLET (NDC 68382062431) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.